



Full year update on Pixium Vision's liquidity agreement

Paris, 26 janvier 2015 - 18h00 – Under the liquidity agreement signed between Pixium Vision and Société de Bourse Gilbert Dupont, the following resources were listed in the liquidity account on December 31st, 2014:

- 26 172 Pixium Vision shares
- 109 232,39 €

It is specified that at the implementation of the contract on July 18, 2014 the following resources were listed in the liquidity account:

- 0 Pixium Vision shares
- 300 000€

About Pixium Vision

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Pixium Vision's VRS are composed of various high-tech elements, associated with a surgical intervention as well as a rehabilitation period. These systems aim to ultimately provide blind patients with vision approaching that of a normal healthy eye.

Clinical trials are currently underway with the VRS IRIS[®] in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. The results of these studies will be used to apply for CE mark. Commercialization of IRIS[®] is expected to begin in 2015.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.



Pixium Vision is listed on Euronext (Compartment C) in Paris.
ISIN: FR0011950641; ticker: PIX

IRIS[®] is a trademark of Pixium-Vision SA

Contacts

Pixium Vision

Pierre Kemula, CFO

contact@pixium-vision.com

+33 1 76 21 47 30

Investors Relations / Press Relations

Citigate Dewe Rogerson

Lucie Larguier – Laurence Bault (Paris)

Mark Swallow – David Dible (London)

pixium-vision@citigate.fr / pixium-vision@citigatedr.co.uk

+33 1 53 32 84 78 / +44 20 7282 2948

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and Pixium Vision (www.pixium-vision.com).